BioCentury
ARTICLE | Finance

Coversin operations

How Celsus, Deerfield grabbed potential best-in-class complement inhibitor

August 24, 2015 7:00 AM UTC

A Deerfield-led investor group has pegged the value of a Phase Ia complement 5 (C5) inhibitor at $150 million and thinks the asset, Coversin, will have a dosing advantage over Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN).

Coversin is owned by Geneva-based Volution Immuno Pharmaceuticals S.A., which is reverse-merging with Celsus Therapeutics plc (NASDAQ:CLTX) to form Akari Therapeutics plc (NASDAQ:AKTX). ...